> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Panel to Mull Opioid Dependence NDA
- URL: https://www.fdaweb.com/joint-panel-to-mull-opioid-dependence-nda/
- Published: 2017-10-03T12:00:00.000Z
- Updated: 2026-09-14T22:53:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139775

*Federal Register* notice: FDA has announced a 10/31 joint advisory committee meeting involving the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Panel members will discuss an Indivior Pharmaceuticals NDA for buprenorphine subcutaneous injection and its use in treating opioid dependence. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-10-03/pdf/2017-21170.pdf?ref=fdaweb.com).